Estimated effectiveness and cost-effectiveness of opioid use disorder treatment under proposed U.S. regulatory relaxations: A model-based analysis.

ABSTRACT:

Aim

To assess the effectiveness and cost-effectiveness of buprenorphine and methadone treatment in the U.S. if exemptions expanding coverage for substance use disorder services via telehealth and allowing opioid treatment programs to supply a greater number of take-home doses of medications for opioid use disorder (OUD) continue (Notice of Proposed Rule Making, NPRM).

Design setting and participants

Model-based analysis of buprenorphine and methadone treatment for a cohort of 100,000 individuals with OUD, varying treatment retention and overdose risk among individuals receiving and not receiving methadone treatment compared to the status quo (no NPRM).

Intervention

Buprenorphine and methadone treatment under NPRM.

Measurements

Fatal and nonfatal overdoses and d

SUBMITTER: Qian G 

PROVIDER: S-EPMC10940194 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature